Stay updated with breaking news from Mark Ragosa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript April 23, 2024 Kiniksa Pharmaceuticals, Ltd. beats earnings expectations. Reported EPS is $-0.00025, expectations were $-0.14. KNSA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) – Equities research analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Kiniksa Pharmaceuticals in a research note issued to investors on Wednesday, February 28th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.17) per share for the quarter. Wedbush […]
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript February 28, 2024 Kiniksa Pharmaceuticals, Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Fourth Quarter and Full […]
Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research report issued to clients and investors on Wednesday, RTT News reports. They presently have a $28.00 price objective on the stock. Wedbush’s price objective would suggest a potential upside of 37.52% from the company’s […]
EAM Investors LLC acquired a new stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 124,438 shares of the company’s stock, valued at approximately $2,161,000. EAM Investors LLC […]